molecules of the year

“Compound 6f”

selective factor XIa serine protease inhibitor

oral in higher species, eff. in thrombosis model

from PK optimization of prior series

J. Med. Chem., May 26, 2020

Bristol Myers Squibb, Princeton, NJ

Structure of compound 6f
1 min read

June’s molecule, the BMS factor XIa inhibitor “Compound 6f”, is a potent, oral macrocyclic factor XIa inhibitor (<1 nM) that was intended as an anticoagulation agent. Since blood clotting is a significant risk for hospitalized patients that must be in a bed for days or weeks, anticoagulants are some of the most prescribed and impactful drugs in the pharmacopeia. “6f” is highly selective against other serine proteases and has excellent oral PK (high bioavailability, low clearance). Though “6f” did not progress due in part to solubility issues, the progress against a challenging target using a difficult macrocyclic scaffold is impressive.

request a trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more.

Interested in learning more? Submit this form to request a trial.

already a member? log in: